Redmile Group LLC Sells 114,979 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Redmile Group LLC cut its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,899,317 shares of the company's stock after selling 114,979 shares during the period. Silence Therapeutics comprises approximately 2.0% of Redmile Group LLC's investment portfolio, making the stock its 24th largest holding. Redmile Group LLC owned 6.35% of Silence Therapeutics worth $34,530,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its position in shares of Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company's stock worth $8,505,000 after buying an additional 321,300 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company's stock worth $9,051,000 after acquiring an additional 208,029 shares during the period. Ikarian Capital LLC boosted its position in Silence Therapeutics by 15.9% in the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company's stock worth $10,678,000 after purchasing an additional 80,678 shares during the last quarter. Janus Henderson Group PLC boosted its position in Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock worth $19,798,000 after purchasing an additional 268,250 shares during the last quarter. Finally, Eventide Asset Management LLC bought a new position in Silence Therapeutics in the 3rd quarter valued at $11,635,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Chardan Capital reissued a "buy" rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. William Blair restated an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, November 15th. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research note on Tuesday, September 3rd. They set a "buy" rating and a $40.00 price target on the stock. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Silence Therapeutics in a report on Monday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $57.20.

Silence Therapeutics Trading Down 1.8 %

Shares of NASDAQ:SLN traded down $0.15 on Thursday, reaching $8.15. 541,743 shares of the company traded hands, compared to its average volume of 259,025. Silence Therapeutics plc has a 52 week low of $5.81 and a 52 week high of $27.72. The business's 50-day simple moving average is $15.23 and its 200 day simple moving average is $17.85. The stock has a market capitalization of $243.91 million, a P/E ratio of -5.19 and a beta of 1.05.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.